Search results for "Drug Safety"
New research looks at drug safety in COVID-19, quarantine length in asymptomatic contacts
Use of immunosuppressive drugs and renin-angiotensin system inhibitors does not appear to adversely affect outcomes in patients with COVID-19, and a seven-day quarantine may be sufficient in asymptomatic contacts with confirmed COVID-19 exposure.
https://acphospitalist.acponline.org/weekly/archives/2021/01/13/1.htm
13 Jan 2021
AHA offers guidance on palliative pharmacotherapy for cardiovascular disease
A scientific statement from the American Heart Association (AHA) calls for use of guideline-directed and evidence-based palliative therapies in end-stage heart failure, pulmonary arterial hypertension, coronary heart disease, and other cardiac conditions.
https://acphospitalist.acponline.org/archives/2024/07/10/aha-offers-guidance-on-palliative-pharmacotherapy-for-cardiovascular-disease.htm
10 Jul 2024
FDA approves self-administration of nasal flu vaccine
The FDA announced that the nasal spray vaccine may now be administered by patients and caregivers, among other recent actions. A prescription is still required.
https://acphospitalist.acponline.org/archives/2024/10/02/fda-approves-self-administration-of-nasal-flu-vaccine.htm
2 Oct 2024
August 14, 2024
ACP Hospitalist provides hospital-based physicians with news and information about the practice of hospital medicine.
https://acphospitalist.acponline.org/archives/2024/08/14/
Calls to poison control centers for gabapentin, baclofen increased in recent years
The increase in exposures to and misuse of these medications in the U.S. may represent an unintended consequence of recent reductions in opioid prescribing for pain management, study authors said.
https://acphospitalist.acponline.org/weekly/archives/2019/12/11/3.htm
11 Dec 2019
Risk for GI events in hospitalized patients similar with newer, older potassium binders
A retrospective study comparing outcomes in U.S. veterans found that risk for intestinal ischemia/thrombosis and a composite outcome of serious gastrointestinal (GI) events was low and did not differ in those who received sodium zirconium cyclosilicate or patiromer and those who received sodium polystyrene sulfonate.
https://acphospitalist.acponline.org/archives/2024/08/14/risk-for-gi-events-in-hospitalized-patients-similar-with-newer-older-potassium-binders.htm
14 Aug 2024
New safety labels added to entire class of fluoroquinolones
Oral and injectable fluoroquinolones are associated with side effects involving tendons, muscles, joints, nerves, and the central nervous system, an FDA safety review found. These side effects may occur hours to weeks after use and can be permanent.
https://acphospitalist.acponline.org/weekly/archives/2016/08/03/5.htm
3 Aug 2016
New drug treats cancer based on biomarker instead of location
Details on the latest warnings, recalls, and approvals.
https://acphospitalist.acponline.org/archives/2017/07/fda.htm
15 Jul 2017
Genetic test for opioid disorder risk approved
The new test is to be used prior to patients' first exposure to oral opioids for the treatment of acute pain. Other recent FDA actions include a recall of overly potent IV drugs.
https://acphospitalist.acponline.org/archives/2024/02/07/genetic-test-for-opioid-disorder-risk-approved.htm
7 Feb 2024
Ondansetron 32-mg dose pulled from market
The 32-mg, single intravenous dose of ondansetron hydrochloride (Zofran) has been pulled from the market due to its cardiac risks, the FDA recently announced.
https://acphospitalist.acponline.org/weekly/archives/2012/12/12/5.htm
12 Dec 2012